Pattern of failure following chemoradiation for locally advanced non-small cell lung cancer: Potential role for stereotactic body radiotherapy

Anticancer Research

Volumn 30, Issue 3, 2010, Pages 953-962

  Nguyen, Nam P ^a   Bishop, Maria ^b   Borok, Thomas J ^c   Welsh, James ^d   Hamilton, Russ ^a   Cohen, Deirdre ^a   Nguyen, L Y M ^e   Vincent, Vinh Hung ^f  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c Borok MDPA   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Chemoradiation; Locally advanced; Non small cell lung cancer; Pattern of failure

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; MITOMYCIN; NAVELBINE; PACLITAXEL; VINBLASTINE; VINDESINE;

ADVANCED CANCER; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISTANT METASTASIS; DRUG MEGADOSE; DRUG TREATMENT FAILURE; ESOPHAGITIS; HUMAN; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MICROMETASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; STEREOTACTIC BODY RADIATION THERAPY; THROMBOCYTOPENIA; TREATMENT FAILURE;

CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; RADIOSURGERY; TREATMENT FAILURE;

EID: 77951078783     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Jemal A, Siegel R, Ward E, Hao Y, Su J, Murray T and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 63: 225-249, 2009.
2. Dillman RO, Hemdon J, Seagren SL, Eaton WL Jr and Green MR: Improved survival in stage III non-small cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 88: 1210-1215, 1996.
3. Sause W, Kolesar P, Taylor S, Johnson D, Livingston R, Komaki R, Emami B, Currran W, Byhardt R, Dar AR and Turrisi A: Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117: 358-364, 2000.
4. Le Chevalier T, Arriagada R, Quoix E, Ruffie P, Martin M, Douillard JY, Tarayre M, Lacombe-Terrier MJ and Laplanche A: Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung carcinoma. Lung Cancer 10: S239-244, 1994.
5. Schaake-Koning C, Van den Bogaert W, Dalesio O, Festen J, Hoogenhout J, Van Houte P, Kirpatrick A, Koolen M, Maat B and Nijs A: Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 326: 524-530, 1992.
6. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N and Arivoshi Y: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 17: 2692-2699, 1999.
7. Schild SE, Stella PJ, Gever SM, Bonner JA, Marks RS, McGinnis WL, Goetz SP, Kuros SA, Mailliard JA, Kugler JW, Schaefer PL and Jett JR: Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 54: 370-378, 2002.
8. Yuan S, Sun X, Li M, Yu J, Ren R, Yu Y, Li J, Liu X, Wang R, Li B, Kong L and Yin Y: A randomized study of involved-field radiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III non-small cell lung cancer. Am J Clin Oncol 30: 239-244, 2007.
9. Ball D, Bishop J, Smith J, O'Brien P, Davis S, Ryan G, Olver I, Toner G, Walker O and Joseph D: A randomized phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multicenter trial. Radiother Oncol 52: 129-136, 1999.
10. Bonner JA, McGinnis WL, Stella PJ, Marschke RF Jr, Sloan JA, Shaw EG, Mailliard JA, Creagan ET, Ahuja AK and Johnson PA: The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma: results of a North Central Cancer Treatment Group phase III study. Cancer 82: 1037-1048, 1998.
11. Huber RM, Flentie M, Schmidt M, Pollinger B, Gosse H, Willner J and Ulm K: Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small cell lung cancer: study CTRT99/97 by the Bronchial Carcinoma Therapy Group. J Clin Oncol 24: 4397-4404, 2006.
12. Vokes EE, Herndon JE, Crawford J, Leopold KA, Perry MC, Miller AA and Green MR: Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 25: 4191-4198, 2002.
13. Gouda YS, Kohail HM, Eldeeb NA, Omar AM, El-Geneidy MM and Elkerm YM: Randomized study of concurrent carboplatin, paclitaxel, and radiotherapy with and without prior induction chemotherapy in patients with locally advanced non-small lung cancer. J Egypt Nat Canc Inst 18: 73-81, 2006.
14. Scagliotti GV, Szczesna A, Ramiau R, Cardenal F, Mattson K, Van Zandwijk N, Price A, Lebeau B, Debus J and Manegold C: Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small cell lung cancer. Br J Cancer 94: 1375-1382, 2006.
15. Nguyen NP, Garland L, Welsh J, Hamilton R, Cohen D and Vinh-Hung V: Can stereotactic fractionated radiation therapy become the standard of care for early stage non-small cell lung carcinoma? Cancer Treat Rev 34: 719-727, 2008.
16. Gettinger S: Targeted therapy in advanced non-small cell lung cancer. Semin Respir Crit Care Med 29: 291-301, 2008.
17. Fournel P, Robinet G, Thomas P, Souquet PJ, Lena H, Vergnenegre A, Delhoume JY, Le Treut J, Silvani JA, Dansin E, Bozonnat MC, Daures JP, Mornex F and Perol M: Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small cell lung cancer. J Clin Oncol 23: 5910-5917, 2005.
18. Komaki R, Scott C, Ettinger D, Lee JS, Fossella FV, Curran W, Evans RF, Rubin P and Byhardt RW: Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer: Radiation Therapy Oncology Group (RTOG) 92-04. Int J Radiat Oncol Biol Phys 38: 149-155, 1997.
19. Jeremic B, Shibamoto Y, Acimovic L, Milicic B, Milisavljevic S, Nikolic N, Dagovic A, Aleksandrovi J and Radosavljevic-Asic G: Hyperfractionated radiation therapy and concurrent low-dose daily, carboplatin/etoposide with or without weekend carboplatin/etoposide chemotherapy in stage III non-small cell lung cancer: a randomized trial. Int J Radiat Oncol Biol Phys 50: 19-25, 2001.
20. Cakir S and Egehan I: A randomized clinical trial of radiotherapy plus cisplatin versus radiotherapy alone in stage III non-small cell lung cancer. Lung Cancer 43: 309-316, 2004.
21. Clamon G, Heamdon J, Cooper R, Chang AY, Rosenman J and Green MR: Radiosensitization with carboplatin for patients with unresectable stage Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol 17: 4-11, 1999.
22. Jeremic B, Shibamoto Y, Acimovic L and Djuric L: Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small cell lung cancer. J Clin Oncol 13: 452-458, 1995.
23. Jeremic B, Shibamoto Y, Acimovic L and Milisavljevic S: Hyperfractionated radiation therapy with or without concurrent low dose daily carboplatin/etoposide for stage III non-small cell lung cancer: a randomized study. J Clin Oncol 14: 1065-1070, 1996.
24. Blanke C, Ansari R, Mantravadi R, Gonin R, Tokars R, Fisher W, Pennington K, O'Connor T, Rynard S and Miller M: Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small cell lung cancer: a Hoosier Oncology Group Protocol. J Clin Oncol 13: 1425-1429, 1995.
25. Dasgupta A, Dasgupta C, Basu S and Majumdar A: A prospective and randomized study of radiotherapy, sequential chemotherapy radiotherapy and concomitant chemotherapy radiotherapy in unresectable non small cell carcinoma of the lung. J Cancer Res Ther 2: 47-51, 2006.
26. Zatloukal P, Petruzella L, Zemanova M, Havel L, Janku F, Judas L, Kubik A, Krepela E, Fiala P and Pecen L: Concurrent versus sequential chemoradiotherapy with vinorelbine and cisplatin in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 46: 87-98, 2004.
27. Belderbos J, Uitterhoeve L, van Zandwijk N, Belderbos H, Rodrigus P, Van de Vaart Price A, van Walree N, Legrand C, Dussenne S, Bartelink H, Giaccone G and Koning C: Randomised trial of sequential versus concurrent chemoradiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer 43: 114-121, 2006.
28. Arvidson NB, Mehta M and Tome W: Dose coverage beyond the gross tumor volume for various stereotactic body radiotherapy planning techniques reporting similar control rates for stage I non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys 72: 1597-1603, 2008.
29. Baagstrom MQ, Stinchcombe TE, Fried DB, Poole C, Hensing TA and Socinski MA: Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: A meta-analysis, J Thorac Oncol 2: 845-853, 2007.
30. Choy H: Chemoradiation in NSCLC: focus on the role of gemcitabine. Oncology (Willinston Park) 18: 38-42, 2004.
31. Caffo O: Radiosensitization with chemotherapeutic agents. Lung Cancer 34: S81-90, 2001.
32. Socinski MA, Blackstock AW, Bogart JA, Wang X, Munley M, Rosenman J, Gu L, Masters GA, Ungaro P, Sleeper A, Green M, Miller AA and Vokes EE: Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small cell lung cancer: CALGB 30105. J Clin Onc 26: 2457-2463, 2008.
33. Kim TY, Yang SH, Lee SH, Park YS, Im YH, Kang WK, Ha, SH, Park CI, Heo DS, Bang YJ and Kim NK: A phase III randomized trial of combined chemoradiotherapy versus radiotherapy alone in locally advanced non-small-cell lung cancer. Am J Clin Oncol 25: 238-243, 2002.
34. Moreno-Jimenez M, Aristu J, Lopez-Picazo JM, Ramos LI, Gurpide A, Gomez-Iturriaga A, Valero J and Martinez-Monge R: Dosimetric analysis of the patterns of local failure observed in patients with locally advanced non-small cell lung cancer treated with neoadjuvant chemotherapy and concurrent conformal (3D-CRT) chemoradiation. Radiother Oncol 8: 342-350, 2008.
35. Onishi H, Araki T, Shirato H, Nagata Y, Hiraoka M, Gomi K, Yamashita T, Nibe Y, Karasawa K, Hayakawa K, Takai Y, Kimura T, Hirokawa Y, Takeda A, Ouchi A, Hareyama M, Kokubo M, Hara R, Itami J and Yamada K: Stereotactic hypofractionated high dose irradiation for stage I non-small cell lung carcinoma. Cancer 101: 1623-1631, 2004.
36. Stinchcombe TE, Morris DE, Lee CB, Moore DT, Hayes DN, Halle JS, Rivera P, Rosenmann JG and Socinski MA: Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose 3-D conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefinitib in unresectable stage IIIA and stage IIIB non-small cell lung cancer. J Thorac Oncol 3: 250-257, 2008.
37. Madani I, De Ruyck K, Goeminne H, De Neve W, Thierens H and Van Meerbeeck J: Predicting risk of radiation-induced lung injury. J Thorac Oncol 2: 864-874, 2007.
38. Shallenkamp JM, Miller RC, Brinkman DH, Foote T and Garces YI: Incidence of radiation pneumonitis after thoracic irradiation: dose-volume correlates. Int J Radiat Oncol Biol Phys 67: 410-416, 2007.
39. Kahn D, Zhou S, Ann SJ, Hollis D, D'Amico TA, Shafman TD and Marks LB: Anatomically correct dosimetric parameters may be better predictors for esophageal toxicity than are traditional CT-based metrics. Int J Radiat Oncol Biol Phys 62: 645-651, 2005.
40. Ceresoli GL, Cattaneo GM, Castellone P, Rizzos G, Landoni, C, Gregorc V, Calandrino R, Villa E, Messa C, Santora A and Fazio F: Role of computed tomography and [18] fluorodeoxyglucose positron-emission tomography image fusion in conformal radiotherapy of non-small cell lung cancer: a comparison with standard techniques with and without nodal irradiation. Tumori 93: 88-96, 2007.
41. De Ruysscher D, Wanders S, Van Haren E, Hochstenbag M, Geeraedts W, Utama I, Simons J, Dohmen J, Rhami A, Buell U, Thimister P, Snoep G, Boersma L, Verschuren T, Van Baardwuk A, Minken A, Bentzen SM and Lambin P: Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small cell lung cancer: a prospective clinical study. Int J Radiat Oncol Biol Phys 62: 988-994, 2005.
42. Gillham C, Zips D, Ponisch F, Evers C, Enghardt W, Abolmaali N, Zophel K, Appold S, Holscher T, Steinbach J, Kotzerke J, Hermann T and Baumann M: Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning? Radiotherapy Oncology 88: 335-341, 2008.
43. Stinchcombe TE, Morris DE, Moore DT, Bechtel JH, Halle JS, Mears A, Deschene K, Rosenman JG and Socinski M: Post-chemotherapy gross tumor volume is predictive of survival in patients with stage III non-small cell lung cancer treated with combined modality therapy. Lung Cancer 52: 67-74, 2006.
44. Stephans KL, Djemil T, Reddy CA, Gajdos SM, Kolar M, Machuzak M, Mazzone P and Videtic GMM: Comprehensive analysis of pulmonary function test (PFT) changes after stereotactic body radiotherapy using dynamic conformal multiple arc therapy. Int J Radiat Oncol Biol Phys 74: 363-369, 2009.
45. Takeda A, Kunieda E, Sanuki N, Ohashi T, Oku Y, Sudo Y, Iwashita H, Ooka Y, Aoki Y, Shigematsu N and Kubo A: Dose distribution analysis in stereotactic body radiotherapy using dynamic conformal multiple arc therapy. Int J Radiat Oncol Biol Phys 74: 363-369, 2009.